Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer;Akciǧer kanserli hastalarin aǧrilarinin tedavisinde transdermal fentanil ve yavaş salinimli morfinin karşilaş tirilmasi

Agri

Volumn 20, Issue 3, 2008, Pages 20-25

  Öztürk, Tülün ^a,b   Karadibak, Kaan ^a   Çatal, Deniz ^a   Çakan, Aydan ^a   Tugsavul, Fevziye ^a   Çirak, Kadri ^a  

^a Izmir Ataturk Training and Research Hospital   (Turkey)

^b CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Cancer related pain; Sustained release oral morphine; Transdermal fentanyl

Indexed keywords

FENTANYL; MORPHINE; NARCOTIC ANALGESIC AGENT;

ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; LUNG TUMOR; MALE; MIDDLE AGED; PAIN; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; FEMALE; FENTANYL; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORPHINE; PAIN; TREATMENT OUTCOME;

EID: 51149084559     PISSN: 13000012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ABPI Data Sheet Compendium. 1995-1996, London: Datapharm, 1995; 724-726.
2. Ahmedzai S, Brooks DJ: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. Pain Symptom Manage. 1997; 13: 254-261.
3. Bonica J: Treatment of cancer pain: Current status and future needs. Adv.Pain Res. Ther. 1985; 9: 589-616.
4. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K: Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin. 2004; 20: 1419-1428.
5. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V; Expert Working Group of the Research Network of the European Association for Palliative Care: Morphine and alternative opioids in cancer pain: the EAPC recom mendations. Br J Cancer 2001; 84(5):587-593.
6. Fitzgibbon DR. Cancer Pain: Management, in Loeser JD. editor. Bonica's Management of Pain. Third edition. Philadelphia: Lippincott Williams & Wilkins 2001. pp. 668-677.
7. Janssen Pharmaceutica. Durogesic (Fentanyl transdermal system) full prescribing information (US). 2001.
8. Menten J, Desmedt M, Lossignol D, Mullie A: Longitidunal follow up of TTS fentanyl use in patients with cancer related pain: results of compassionate use study with special focus on elderly patients. Curr Med Res Opin 2003; 18(8): 488-498.
9. Mercadante S: Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 1999; 86(9): 1856-1866.
10. Muijsers RB, Wagstaff AJ: Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15):2289-2307.
11. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R: Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol. 1998;16 (4): 1588-1593.
12. Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA: Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14: 111-119.
13. Ripamonti C, Fagnoni E, Campa T, Brunelli C and Conno F: Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Supportive Care in Cancer 2006; 14(5): 400-407.
14. Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW: Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19(6): 457-469.
15. Solassol I, Caumette L, Bressolle F, Garcia F, Thezenas S, Astre C, Culine S, Coulouma R, Pinguet F: Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep. 2005;14(4):1029-1036.
16. Southam MA: Transdermal fentanyl therapy: System design, pharmacokinetics and efficacy. Anticancer drugs 1995; 6:29-34.
17. Wong JO, Chiu GL, Tsao CJChang CL: Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin. 1997; 35 (1): 25-32.
18. World Health Organization. Cancer pain relief and palliative care:report of a WHO expert commitee, 2nd ed. Geneva: World Health Organization Tecnical Report Series; 1996.
19. World Health Organization (WHO) handbook for reporting results of cancer treatment (Geneva off - set publication vol 48). Geneva: WHO, 1979.